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Direct Detection and Genotyping of Klebsiella pneumoniae
Carbapenemases from Urine by Use of a New DNA Microarray Test
Harald Peter,a Kathrine Berggrav,a Peter Thomas,a Yvonne Pfeifer,b Wolfgang Witte,b Kate Templeton,c and Till T. Bachmanna
Division of Pathway Medicine, University of Edinburgh, Medical School, Edinburgh, United Kingdoma; Robert Koch Institute, Nosocomial Infections, Wernigerode,
Germanyb; and Microbiology, NHS Lothian, Edinburgh, United Kingdomc
Klebsiella pneumoniae carbapenemases (KPCs) are considered a serious threat to antibiotic therapy, as they confer resistance to
carbapenems, which are used to treat extended-spectrum beta-lactamase (ESBL)-producing bacteria. Here, we describe the de-
velopment and evaluation of a DNAmicroarray for the detection and genotyping of KPC genes (blaKPC) within a 5-h period. To
test the whole assay procedure (DNA extraction plus a DNAmicroarray assay) directly from clinical specimens, we compared
two commercial DNA extraction kits (the QIAprep Spin miniprep kit [Qiagen] and the urine bacterial DNA isolation kit [Nor-
gen]) for the direct DNA extraction from urine samples (dilution series spiked in human urine). Reliable single nucleotide poly-
morphism (SNP) typing was demonstrated using 1 105 CFU/ml urine for Escherichia coli (Qiagen and Norgen) and 80 CFU/ml
urine, on average, for K. pneumoniae (Norgen). This study presents, for the first time, the combination of a new KPCmicroarray
with commercial sample preparation for detecting and genotyping microbial pathogens directly from clinical specimens; this
paves the way toward tests providing epidemiological and diagnostic data, enabling better antimicrobial stewardship.
The increasing prevalence of carbapenem-resistant Enterobac-teriaceae (CRE) is a growing public health concern (24, 30, 33).
Resistance conferred by the Klebsiella pneumoniae carbapen-
emases (KPCs) in particular is an emerging problem of significant
clinical importance (25). KPC enzymes are class A beta-lactama-
ses, which confer resistance to penicillins, cephalosporins, mono-
bactams, and carbapenems (17). KPCs were first identified in a
multidrug-resistant Klebsiella pneumoniae isolate from a hospital
in the United States in 1996 but have since then spread worldwide
and to other Gram-negative species, like Escherichia coli andAcin-
etobacter baumannii (17, 35). Due to a lack of new antibiotics,
there is only a limited number of treatment options left against
carbapenemase-producing bacteria, such as the last-line drugs
polymyxin B and colistin, which have been associated with high
rates of nephrotoxicity (16). In addition, recent reports have even
shown the appearance of a KPC-producing K. pneumoniae isolate
that is also resistant to colistin (2, 20, 41).
In order to reduce and control the further spread of carbap-
enem resistance, rapid identification is crucial so that appropriate
treatment can be applied (18). Classical microbiological methods
are often slow and give results only after additional cultivation for
24 or even 48 h (24, 34). To address this problem, a variety of
molecular methods have been developed, such as PCR or real-
time PCR assays detecting carbapenemase genes (3, 6, 11, 13, 19,
32). PCR-based methods are a lot quicker than microbiological
methods and can give results within a few hours. However, these
methods lack the ability to detect single nucleotide polymor-
phisms (SNPs), which are helpful for detailed outbreak investiga-
tion and epidemiological studies. Currently, there are 11 pub-
lished KPC variants (KPC-2 to KPC-12), which differ from each
other only in single point mutations. For each variant, slightly
different carbapenem MIC values and efficacies of beta-lactam
inhibitors, like clavulanic acid, have been observed. KPC-2 and
KPC-6 especially seem to confer resistance to all carbapenems,
whereas other variants show less activity against imipenem or
meropenem (36, 45). To identify all the different variants, se-
quencing is the gold standard, but this method is very time con-
suming and too demanding for routine clinical diagnostics. An
alternative method is the use of a DNA microarray, which allows
for rapid identification of SNPs and parallel detection of several
resistance genes (4, 5, 7, 14, 15, 22, 23, 44, 47). However, the
currently described methods for KPC gene detection (the Check-
MDR CT101, CT102, and CT103 assays and Check-KPC extend-
ed-spectrum beta-lactamase [ESBL] microarray [Check-Points
Health BV, Wageningen, Netherlands] and the hyplex SuperBug
ID test system [Amplex BioSystems GmbH, Gießen, Germany])
do not allow for differentiation between the KPC variants. Here,
we report the development and evaluation of a newDNAmicroar-
ray, which is capable of SNP detection, allowing an identification
of all variants fromKPC-2 to KPC-11 directly from urine samples
and without prior growth in culture.
MATERIALS AND METHODS
The new KPCmicroarray was designed to run under the same conditions
as our previously developed ESBLmicroarray (15).We evaluated the per-
formance of this new microarray on characterized reference strains and
analyzed its detection limits. We further tested the performance of the
microarray to identify KPC variants directly from urine samples without
further cultivation. For this, we used two different DNA extraction kits,
the QIAprep Spin miniprep kit (Qiagen) and the urine bacterial DNA
isolation kit (Norgen), and validated their performances in combination
with the KPC microarray. Urine samples that were spiked with different
dilutions of E. coli or K. pneumoniae reference strains, carrying different
variants of the blaKPC gene, were used as the testing material.
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Reference strains. Twelve well-characterized reference strains carry-
ing blaKPC-type genes were used for the development and validation of the
microarray probes and primers. E. coli (producing KPC-2) and K. pneu-
moniae (KPC-2 and KPC-3) were from the Robert Koch Institute, Wer-
nigerode, Germany (31), and K. pneumoniae (KPC-3) was from the
Health Protection Agency, United Kingdom (46). Three strains of K.
pneumoniae—VIN, AUB, andGOU (KPC-2)—were provided by the Ho-
pital Paul Brousse, France (12), and another five strains—VA 367 (KPC-
3), VA 375 (KPC-3), VA 361 (KPC-2), VA 184 (KPC-2), and VA 406
(KPC-2)—were provided by Robert Bonomo from the Louis Stokes
Cleveland VA Medical Center (8). All isolates were cultivated at 37°C in
Luria-Bertani (LB) medium.
Spiking of urine samples and DNA extraction. Noninfected urine
samples (tested by routine microbiological culture) from several patients
(New Royal Infirmary, Edinburgh, United Kingdom) were pooled and
subsequently spikedwith reference strains carrying variants of blaKPC. For
an accurate determination of the limit of detection (LOD), dilution series
of bacteriawere produced in urine, covering a range from1 to 109CFU/ml
urine in 11 dilution steps. The number of bacteria in each dilution step
was determined via the counting of colonies on LB agar plates in dupli-
cate. CFU numbers that were too large to be counted were extrapolated
from the lower concentrations.Dilution series tests were carried out for all
three strains received from the Robert Koch Institute (E. coli [KPC-2], K.
pneumoniae [KPC-2], and K. pneumoniae [KPC-3]). After spiking of the
urine samples, each tube wasmixed and set aside at room temperature for
30 min. Before the DNA extraction procedures were applied, 100 l of
each dilution step was used to determine the exact number of CFU/ml in
the urine by plating onto LB agar.
During DNAmicroarray development, plasmid DNA from each clin-
ical isolate was extracted from 2 ml overnight culture using the QIAprep
Spin miniprep kit (Qiagen, Hilden, Germany). For the detection study of
clinical specimens, plasmidDNA from spiked urine sampleswas extracted
from 1.7ml of urine using the QIAprep Spinminiprep kit (Qiagen) or the
urine bacterial DNA isolation kit (Norgen, Thorold, Canada), both of
which were applied according to the manufacturer’s instructions.
Target DNA preparation. The target DNA used for the hybridization
onto the oligonucleotidemicroarrays was synthesized via PCR. The prim-
ers used for the amplification of the blaKPC gene were the forward primer
KPC_PR_F1 (5=-TGTCACTGTATCGCCGTG-3=) (48) and the reverse
primerKPC_PR_R2 (5=-TTGACGCCCAATCCCT-3=), developed as part
of this study. The amplicon was expected to be 871 bp in length. The
amplification and labeling of blaKPC took place in a total reactionmixture
volume of 30l using the following reagents: 0.4Meach primer, 1Taq
buffer, 1 mM MgCl2, 3 U of HotStar Taq polymerase (Qiagen, Hilden,
Germany), 0.1 mM each dATP, dGTP, and dTTP, 0.06 mM dCTP, and
0.04 mM cyanine 3 (Cy3)-dCTP (Fisher Scientific, Leicestershire, United
Kingdom). The reactions were carried out on a Techne TC-512 thermo-
cycler (Keison Products, Essex, United Kingdom) using an initial dena-
turing and activation step at 95°C for 15 min followed by 40 cycles con-
sisting of 30 s of denaturing at 94°C, 30 s of annealing at 54°C, and 1 min
of elongation at 72°C, followed by a final extension step at 72°C for 10
min. The PCR product was purified using the QIAquick Spin PCR puri-
fication kit (Qiagen) following the standard instructions and a final elu-
tion in 30 l double-distilled water (ddH2O). The DNA yield and rate of
Cy3-dCTP incorporation, expressed as the quotient of the number of
nucleotides and the number of incorporated fluorescent dyes (NT/F),
were determined by measuring the absorption at 260 and 550 nm (ND-
1000 spectrophotometer; Nanodrop Technologies, Rockland, DE). Di-
rectly before hybridization, the labeled target DNA was fragmented for 5
min at room temperature using 0.8 mU DNase I (Promega, Mannheim,
Germany) for each ng DNA in a total reaction mixture volume of 40 l
containing 1 DNase buffer. The reaction was stopped through the ad-
dition of 3 mM EGTA and incubation at 65°C for 10 min. The fragmen-
tation efficiency was estimated by capillary gel electrophoresis using a
DNA1000 LabChip kit (Bioanalyzer 2100; Agilent, Böblingen, Germany).
Oligonucleotide microarray fabrication. The following protocol is
based on our previously published array production methods (15). All
oligonucleotide capture probes were purchased fromMetabion (Martin-
sried, Germany) and diluted to a final concentration of 20M in spotting
buffer (Nexterion Spot I and Spot III, in a 1:3 ratio). Each probe had an
11-thymidine spacer and an amino modification at the 5= end. Using a
contact printer (MicroGrid II; BioRobotics, Cambridge, United King-
dom) with split pins (MicroSpot 2500; BioRobotics), each probe was
spotted in triplicate onto epoxy-coated slides (Nexterion Slide E; Schott,
Jena, Germany). A total of 4 arrays were printed per slide. In order to
immobilize the probes after spotting, the slides were incubated for 30min
at 60°C in a drying oven (Memmert, Schwabach, Germany). At this stage,
the slides could be stored for several months. Before hybridization, the
slides were rinsed for 5 min in 0.1% (vol/vol) Triton X-100, for 4 min in
0.5 l of concentrated HCl per ml of ddH2O, for 10 min in 100 mMKCl,
and finally for 1 min in ddH2O. Subsequently, the slides were blocked for
15 min at 50°C in blocking solution containing 0.3% (vol/vol) ethanol-
amine in 100 mM Trizma base adjusted to pH 9 with HCl. Finally, they
were rinsed for 1min in ddH2O and spun dry at 1,300 rpm for 2min in an
Eppendorf 5810 R centrifuge (Eppendorf AG, Hamburg, Germany)
equipped with swing-bucket rotor adapters for 96-well plates using a
metal slide rack (Lipshaw, Detroit, MI). In addition to blaKPC-specific
probes, several control probes were included on each array: a prelabeled
spotting control (5=-TTTTTTTTTTTTCTAGACAGCCACTCATA-Cy3-
3=), a positive hybridization control (5=-TTTTTTTTTTTGATTGGACG
AGTCAGGAGC-3=) complementary to a labeled oligonucleotide target
(5=-Cy3-GCTCCTGACTCGTCCAATC-3=), whichwas spiked during hy-
bridization, and a negative control (5=-TTTTTTTTTTTTCTAGACAGC
CACTCATA-3=). All control sequences were derived from Arabidopsis
thaliana and are very distant from any target sequences found in bacteria.
Spotting controls were spotted at every corner of each subarray (10 M),
whereas positive and negative controls were distributed alternately along
the sides of each subarray.
Hybridization and washing. For the analysis of KPC strains, 100 ng
target DNA was used for hybridization onto each microarray. In the case
of the dilution series, the total amount of target DNA received from the
labeling PCR was used for hybridization (28 l) and ranged from 1 to
1,600 ngDNA. For hybridization, the target DNAwas supplemented with
0.2 pmol of oligonucleotide complementary to the positive hybridization
control in 100l with 2 SSPE (20 SSPE: 3MNaCl, 200mMNaPO4, 20
mM EDTA [pH 7.4]) and 0.01% SDS. The hybridization was performed
in an Agilent microarray hybridization chamber using gasket slides to
cover the microarray, with incubation for 1 h at 47°C in an Agilent hy-
bridization oven at 6 rpm (Agilent Technologies). After hybridization, the
slides were washed at room temperature for 10 min each in 2 SSC (20
SSC: 3 M NaCl and 0.3 M sodium citrate) with 0.2% SDS, 2 SSC, and
0.2 SSC. Subsequently, the slides were dipped in ddH2O for less than 2
s and spun dry at 1,300 rpm for 2 min in an Eppendorf 5810 R centrifuge.
At this point, the slides could be stored at room temperature until scan-
ning.
Image acquisition and data analysis.After hybridization, the fluores-
cent signals were acquired with a Tecan LS reloaded laser scanner (Tecan
Austria GmbH, Grödig, Austria) at 532 nm and a 575-nmCy3 filter. Each
slide was scanned with 3 different photomultiplier tube (PMT) gain set-
tings (150, 180, and 200), using a resolution of 10m. The quantification
of signal intensities was performed using QuantArray Analysis Software
(Packard BioChip Technologies, Billerica, MA) followed by data analysis
and processing in Microsoft Excel (Microsoft, Redmond, WA). First, the
local background of each spot was subtracted from the raw spot intensity
value, followed by the calculation of themeannet signal intensity (NI) and
standard deviation (SD) of the three replicates. Within each probe set
(probes interrogating onemutation site), the probewith the highest signal
intensity was termed the perfect match (PM), whereas the remaining
probes were marked as mismatches (MM). In order to evaluate the per-
formance of each probe set, the ratios between the MM and PM signal
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intensities were calculated. The larger the relative difference between the
MM and PM signals, the better the discriminative power of the probe set.
The MM probe with the highest signal intensity was used for the calcula-
tion of the relative signal intensity [RImax(MM)NImax(MM)/NIPM]. Only
the probe sets that showed performances with RImax(MM) values of0.7
were used for analysis. The use of this threshold has been proven to result
in high-quality discriminations (10, 15). In addition to the RI value, the
limit of detection (LOD) was used to evaluate performance of the probe
sets. The LOD was calculated based on the maximum signal intensity
(NImax) obtained within each probe set, based on a no-template control
(NTC) hybridization plus 3 times the highest standard deviation [LOD
NImax (3 SDmax)]. Only probe sets with perfect-match signal inten-
sities above the limit of detection (NIPMLOD)were used for analysis. In
addition, the coefficient of variation (CV) was calculated for each set of
replicate probes (CV  SD/NIPM). Probe sets with CV values of 30%
were flagged and excluded from analysis to ensure that only the probe
signals with high reproducibility were used for the analysis. The correct
blaKPC variant was then identified based on the combination of all valid
perfect-match signals. The KPC variants and their single nucleotide poly-
morphisms (SNPs) used for identification corresponded to recently pub-
lished data (3). The mathematics described above were applied automat-
ically using Excel (Microsoft) using the input of the raw quantification
files obtained from QuantArray to identify the correct KPC variant.
RESULTS
Construction of theKPCmicroarray. In this study, we developed
a DNAmicroarray for the rapid detection of KPC beta-lactamase
(blaKPC)-positive bacteria, which is capable of distinguishing be-
tween the different KPC variants. The probes used for the DNA
microarray were designed to identify single nucleotide changes in
the four mutation hot spots (positions 147, 308, 716, and 814) of
the blaKPC gene, allowing an identification of all known KPC vari-
ants (3). For each position of interest, two sets of probes were
designed, sense and antisense probes, resulting in a very robust
detection system. Each probe consisted of a 16- to 19-bp oligonu-
cleotide with a 13-thymidine spacer and aC6-aminomodification
at the 5= end. All 32 oligonucleotide probes and the two primers
that were used are listed in Table 1. The array layout as shown in
Fig. 1 can easily be expanded in the future by the addition of new
probes to cover potential KPC variants with different mutation
hot spots.
Validation of the DNA microarray using reference strains.
The performance of the KPC microarray was validated using 12
well-characterized KPC-producing reference strains, which were
all identified correctly. In all cases, the Cy3 labeling PCR amplifi-
cation yielded, as expected, an 871-bp product in a concentration
range of 15 to 25 ng/l. The rate of label incorporation, the num-
ber of nucleotides per number of incorporated fluorescent dyes
(NT/F), varied between 34 and 76, depending on the quality of the
template DNA. The best results were obtained using 200 ng la-
beled DNA product per microarray (2 ng/l), but as little as 50 ng
(0.5 ng/l) was sufficient in all cases for the correct identification
of each variant (equivalent to 870 pmol/liter). The performance of
each probe set was measured using the maximum mismatch-to-
perfect-match ratio (MMmax/PM).With only one exception, these
values were always below 0.7 for all tested reference strains, defin-
ing a high level of discrimination for each probe set. In the single
exception, the antisense probe for position 716 had aMMmax/PM
of 0.711, inwhich case the sense probewas used for discrimination
instead with a MMmax/PM value of 0.54. Based on all reference
strain hybridizations, the best discrimination for the sense probes
was achieved with the probe set SNP-147, which had a median
relative intensity value (MMmax/PM) of 0.037, followed by SNP-
308 (0.055), SNP-814 (0.377), and SNP-716 (0.526). For the an-
tisense probes, the best discrimination was achieved with probe
set SNP-308,which had amedian relative intensity value (MMmax/
PM) of 0.041, followed by SNP-814 (0.09), SNP-147 (0.133), and
SNP-716 (0.347). Figure 1B and C shows, as an example, the rel-
ative fluorescent signal intensities of all sense and antisense probes
obtained through hybridization with target DNA from K. pneu-
moniae carrying the blaKPC-3 variant. The relative intensity values
between the maximum mismatch and perfect-match signal
(MMmax/PM) are also included in Fig. 1. Both the sense and anti-
sense probes identified variant KPC-3 correctly. The results of all
other strains are shown in Fig. S1 (KPC-2) and S2 (KPC-3) in the
supplemental material.
Microarray limit of detection. Before the limit of detection
(LOD)of thewhole assaywas analyzed, the LODof themicroarray
to labeled target DNA itself was tested. For this purpose, a dilution
series of labeled target DNA (2 to 100 ng) was made, amplified
from E. coli (KPC-2). Before hybridization, two differentmethods
of target DNA treatment were applied, one using aDNase concen-
tration adjusted to the actual amount of target DNA and the other
using a fixed concentration independent of the amount of target
DNA (resembling the clinical test situation, where the amount of
TABLE 1 blaKPC primer and oligonucleotide probe sequences
Oligonucleotide namea 5=–3= sequenceb,c Position/SNP in blaKPC Tm (°C)d Reference
KPC_SNP1_s TGTACGCGATNGATACCGG 147 55.4 This study
KPC_SNP1_as CCGGTATCNATCGCGTACA 147 55.4 This study
KPC_SNP2_s GCTGGTTCNGTGGTCAC 308 54.9 This study
KPC_SNP2_as GTGACCACNGAACCAGC 308 54.9 This study
KPC_SNP3_s TGCGGAGNGTATGGCA 716 55.2 This study
KPC_SNP3_as TGCCATACNCTCCGCA 716 55.2 This study
KPC_SNP4_s GATGACAAGNACAGCGAGG 814 54.5 This study
KPC_SNP3_as CCTCGCTGTNCTTGTCATC 814 54.5 This study
KPC_PR_F1 TGTCACTGTATCGCCGTC 2–20 54.5 48
KPC_PR_R2 AGGGATTGGGCGTCAA 857–872 53.8 This study
a Every probe was spotted as sense (s) or antisense (as).
b For each single nucleotide polymorphism (SNP) position, four probes were designed that differ only at their central bases (N A, G, C, or T). The relevant nucleotide triplets are
underlined.
c Every probe was modified with a 13-thymidine spacer and a C6-amino modification at the 5= end.
d The melting temperatures (Tm) were calculated with the OligoAnalyzer (Integrated DNA Technologies) using default parameters.
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DNA would be unknown). For the adjusted protocol, a DNase
concentration of 0.8 mUDNase for each ng DNAwas found to be
most efficient, whereas for the fixed concentration experiment, 16
mU DNase was used, optimized to an average amount of 20 ng
target DNA. The first method was more accurate but also more
time consuming, due to the additional purification andmeasuring
steps, which are necessary to acquire the exact concentration of
the target DNA. The second method using a fixed amount of
DNase would be the more practical solution in terms of develop-
ing an automated diagnostic tool, which contributes to a signifi-
cant reduction in assay time. A comparison of the microarray
results using both methods is shown in Fig. 2. With the adjusted
method (Fig. 2A), the correct KPC variant was detected using as
little as 10 ng of target DNA (equivalent to 170 pmol/liter),
whereaswhenusing a fixed amount ofDNase (Fig. 2B), the correct
KPC variant was identified using as little as 20 ng target DNA (350
pmol/liter). Hybridizations using the adjusted method resulted
generally in higher absolute fluorescent signals as well as better
(lower) MM/PM ratios. Therefore, this method was applied to all
the following experiments.
Limit of detection estimated directly from spiked urine sam-
ples. In order to determine the limit of detection (LOD) of the
whole assay, uninfected urine samples were pooled and subse-
quently spiked with bacteria carrying variants of the blaKPC gene.
These samples were diluted in 11 steps, resulting in dilution series
covering a range of 1 to 109 CFU/ml urine, confirmed via colony
counts on LB agar plates. All dilution series were counted at least
in duplicate. Several dilution series were produced using E. coli
blaKPC-2, K. pneumoniae blaKPC-2, and K. pneumoniae blaKPC-3.
Subsequently, plasmidDNAwas extracted fromeach dilution step
using the QIAprep Spin miniprep kit (Qiagen) and the urine bac-
terial DNA isolation kit (Norgen, Thorold, Canada) in duplicate.
Nonspiked urine samples were extracted as well and were used as
no-template controls (NTC). The extracted DNA was amplified
and analyzed using the DNA microarray. As an example, Fig. 3A
and B shows the data obtained from analyzing a dilution series of
K. pneumoniae (KPC-3) extracted with the QIAprep Spin mini-
prep kit. KPC-3 was correctly identified at a concentration of 4
103 CFU/ml urine. One dilution step further (360 CFU/ml), the
criteria for a correct identification were not fulfilled anymore. At
this dilution step, the mismatch-to-perfect-match ratio (MM/
PM) for one SNP position (SNP-716) was below the threshold of
0.7 for both probe sets (sense/antisense), and in addition, the limit
of detection for more than one probe set was reached. Figure 3C
andD shows the corresponding data obtainedwith themicroarray
after extraction using the urine bacterial DNA isolation kit from
Norgen. The correct identification of the variant KPC-3 using this
method was still possible from a dilution containing 360 CFU/ml
urine.
Figure 4 shows a summary of all 132 DNA microarray experi-
ments carried out to determine the limit of detection for thewhole
assay. E. coli (KPC-2), which was spiked into urine samples, was
FIG 1 (A, left panel) Typical fluorescent image of a DNAmicroarray hybridized with blaKPC target DNA fromKlebsiella pneumoniae (Health Protection Agency
[HPA] isolate) carrying variant KPC-3. (A, right panel) KPC DNAmicroarray layout. All relevant SNP positions are covered by a set of 8 probes (all four bases
as sense and antisense) spotted in triplicate. The perfect-match positions aremarked with black circles corresponding to the blaKPC-3 variant. The bottom images
represent the resulting relative fluorescent signal intensities of sense (A) and antisense (B) probes hybridized. The corresponding perfect-match signal patterns
from the sense (GCTT) and antisense (CGAA) probes identified variant KPC-3 correctly. The combined analysis of sense and antisense strands increases the
robustness of the system. The numbers represent the mismatch-to-perfect-match ratios (MM/PM), a measure for the discriminative power of each probe set. In
general, the probe sets with MM/PM ratios larger than 0.7 were omitted from the analysis. The respective SNP was then covered by the corresponding
sense/antisense probe set.
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still identified correctly at a concentration of 1.6  104 CFU/ml
urine in all cases. For E. coli (KPC-2), the LOD results were the
same for all replicates carried out with the Qiagen extraction kit as
well as the urine extraction kit fromNorgen (Fig. 4A). The cells of
K. pneumoniae (KPC-2) were still identified correctly to a concen-
tration of 120 CFU/ml urine with the Norgen and Qiagen kits.
One of the Norgen extractions allowed the correct identification
of the KPC-2 variant from as little as 40 CFU/ml urine (Fig. 4B).
The third tested strain, K. pneumoniae (KPC-3), was identified
correctly at a concentration of 4  103 CFU/ml urine using the
Qiagen extraction kit for both replicates, whereas the Norgen kit
allowed an identification at 360 CFU/ml urine (80 CFU/ml in one
of the replicates) (Fig. 4C). Over all experiments, the LOD seemed
to be higher for urine samples spiked with E. coli (1.6  104
CFU/ml urine) and lower for those spikedwithK. pneumoniae (40
to 4,000 CFU/ml urine). In addition, we observed that the Norgen
kit gave slightly higher yields than the Qiagen kit when extracting
DNA from K. pneumoniae, resulting in a lower LOD. A more-
detailed table containing all absolute PM signal intensities and the
corresponding MMmax/PM ratios can be found in Fig. S3, S4, and
S5 in the supplemental material. When processing 20 urine sam-
ples in parallel, the extraction using the urine bacterial DNA iso-
lation kit (Norgen) took 2 h, on average, resulting in a total time to
results of 6 h after urine sampling. When applying the QIAprep
Spin miniprep kit (Qiagen), the extraction took 1 h, on average,
for 20 urine samples, resulting in a total time to results of 5 h.
DISCUSSION
The rapid detection of antibiotic resistance in clinical samples is
crucial in order to provide appropriate treatment for patients in a
timely manner. ESBLs and carbapenemases especially have be-
come worldwide threats to successful antibiotic therapy. In par-
ticular, KPC carbapenem resistance has been reported increas-
ingly in recent years, resulting in a need for new and rapid
detection methods. Conventional routine methods are mostly
based on phenotypical detection procedures. An example is the
modified Hodge test, which can confirm the presence of carbap-
enemases but cannot distinguish between KPC and other carbap-
enemases (25, 29). To distinguish KPCs from other carbapenem
producers, boronic disk tests can be used (42, 43), but still, the
identification of single KPC variants is not possible. In general, all
phenotypic methods are very time consuming, delivering results
often only after 1 or 2 days (24). Faster are the molecular tests,
such as real-time PCR assays, allowing for quick identification of
KPCgenes (3, 6, 11, 13, 18, 21, 24).Nevertheless, these assays often
have only a limited multiplexing capability and also cannot dis-
tinguish single KPC variants from each other.
Therefore, DNA microarrays are a good alternative, offering a
FIG2 Limit of detection of theDNAmicroarray using dilutions of targetDNA.Adilution series of labeled targetDNA (2 to 100 ng)was hybridized onto theKPC
microarray to identify its LOD. (A) Absolute fluorescent signal intensities obtained after the hybridization of target DNA, which was digested with 0.8 mU
DNase/ng DNA. The identification of KPC-2 was possible with as little as 10 ng target DNA. a.u. indicates arbitrary units. (C) The DNAwas digested with a fixed
amount ofDNase (16mU),which is equivalent to the amount used for 20 ng (panel A).Here, as little as 20 ng targetDNA/microarraywas still correctly identified.
(B and D) CorrespondingMM/PM ratios. At 20 ng target DNA/microarray, the SNP-814 sense probe was out of range (MM/PM 0.7); therefore the antisense
probe was used for discrimination instead, which still correctly identified variant KPC-2. For all following experiments, the method presented in panels A and B
(0.8 mU DNase/ng DNA) was used due to its higher reproducibility and sensitivity.
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high multiplexing capability, and furthermore allow for the iden-
tification of SNPs, which is necessary to distinguish between single
variants. The possibility of identifying single variants from each
other using a DNA microarray has been demonstrated for the
ESBL-relevant genes blaTEM, blaSHV, and blaCTX-M (10, 15). The
commercially available microarray assays from Check-Points en-
able only the identification of genes and mutation hot spots rele-
vant to resistance caused by ESBLs and carbapenemases, including
the detection of blaKPC (4, 5, 7, 9, 22, 23, 44, 47). However, the
Check-Points system can be used as a reliable screening tool to
guide PCR sequencing, allowing in this way an identification of
single variants (14).
The capability to identify single variants of the KPC genemight
not have been a requirement in the past, as there were only a very
limited number of KPC variants reported showing very similar
phenotypes. However, recent studies have suggested that an in-
creasing number of different KPC variants confer different resis-
tance profiles. Knowing which variant is present might open new
treatment options in the future, especially under strict antibiotic
stewardship. The difference in resistance profiles and their effects
on beta-lactam inhibitors were demonstrated directly in clinical
samples and transformants with KPC variants and through com-
parisons of hydrolytic activities (1, 27, 28, 37, 45). Robledo et al.
(36) reported a variation of antimicrobial susceptibility to carbap-
enems depending on the KPC variant during a 1-year study based
on KPC-producing isolates taken from 6 Puerto Rico Medical
Center hospitals. All isolates were resistant to ertapenem irrespec-
tive of the KPC variant. Isolates with KPC-2 and KPC-6 were
resistant to all carbapenems tested. Isolates with KPC-4 were sus-
ceptible to imipenem and meropenem, while those with KPC-3
demonstrated variable susceptibility (36). Therefore, knowing the
exact KPC variant might allow for a more target-driven use of
individual carbapenems or beta-lactam inhibitors. However, the
greatest benefit of SNP detection in blaKPC genes is the application
in epidemiological studies to examine if the resistance found is a
single case or a pandemic (10).
The KPC microarray described here was able to identify and
distinguish all KPC variants that were published at the time of
design (KPC-2 to KPC-11). These variants differ from each other
in 4 SNP positions (nucleotides 147, 308, 716, and 814). The re-
cently reported variant KPC-12 (see www.lahey.org/Studies/) dif-
fers from KPC-2 by a single mutation at SNP position 502, a new
position, which is not covered in the current version but could
easily be added to future versions of this microarray. Therefore,
KPC-12 would currently be identified as KPC-2 using the mi-
croarray. Due to the selected melting temperatures of the probes
and primers, the KPCmicroarray could be used together with our
existing ESBLmicroarray (15), or both could be spotted onto one
new microarray in the future by applying the same reaction con-
ditions.
FIG 3 Analysis of limit of detection (LOD) directly from urine samples. Overnight cultures of Klebsiella pneumoniae carrying blaKPC-3 were spiked into urine
samples in a dilution series from 4 107 to 1 CFU/ml urine. The samples were then left for 30 min at room temperature before the DNA was extracted. In this
example, the QIAprep Spin miniprep kit (Qiagen) was used for extraction. (A) Absolute fluorescent signal intensities of 2 sense and 2 antisense perfect-match
probes obtained after DNAmicroarray analysis of the extracts from each dilution. (B) The mismatch-to-perfect-match ratios of the same probes are presented,
showing data up to the dilution step at which a good discrimination (MM/PMof0.7) was possible. In this case, KPC-3 was still identified correctly to a dilution
step of 4,000CFU/ml urine. The identified variant is shownunderneath the concentration. (C andD)Data obtained from the same dilution series after extraction
using the urine bacterial DNA isolation kit (Norgen).With thismethod, the correct KPC variant was still identified from a dilution containing 360CFU/ml urine.
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The KPC microarray was tested successfully on 12 different
reference strains carrying either variant KPC-2 or KPC-3. These
are the most frequently found KPC variants. During the course of
the project, we had no access to any other KPC variants. Never-
theless, all probe sets could still be validated due to the fact that
each probe set is covered by the amplicon used. Each probe set
gave a clear positive hybridization signal with a high level of dis-
crimination between perfect-match and mismatch probes when
being tested with KPC-2 or KPC-3. Consequently, there are no
untested probes on the array. We would consider this to be suffi-
cient at this stage, as themethod of allele-specific hybridization for
SNP detection using microarrays is well established, and all probe
sets were tested positive in over 160 separate hybridization exper-
iments. Although theoretically possible, we did not design syn-
thetic targets to test all possible hybridization patterns (all variants
for each position), as this would have gone beyond the scope of the
study while giving only a limited scientific benefit due to the dif-
ferences in PCR amplicons and synthetic targets. The limit of de-
tection for labeled target DNA was found to be 10 ng per assay
when a DNase amount that was adjusted to the target DNA con-
centration was used. When a fixed DNase amount, optimized for
20 ng target DNA, was used, the limit of detection also turned out
to be 20 ng. Smaller DNA amounts were probably overdigested
and could therefore not be detected anymore. Higher fluorescent
signals and better discrimination values (MM/PM) were obtained
using the adjusted method. With the adjusted method, a total
assay time of 3.5 h after DNA extraction was possible, which is
significantly shorter than conventional PCRs followed by se-
quencing or phenotypical methods that require 1- or 2-day over-
night cultivation (26, 39, 40). By using a fixed amount of DNase
before hybridization, this assay time could be reduced by at least
30 min, which would otherwise be necessary for DNA purifica-
tion, concentration measurements, and final digestions. There-
fore, this microarray has the potential to be used as a rapid KPC
resistance test.
Disregarding the much faster time to results, the introduction
of molecular assays into routine diagnostics depends on the cost.
In general, molecular assays are still more costly than culture-
based tests. Commercially available molecular assays currently
have prices of approximately $19 (real-time PCR [RT-PCR]) to
$40 (microarrays) per sample. For our KPCmicroarray, we calcu-
lated a price of $38 per sample, which includes array production,
DNA extraction from urine samples, and consumables for run-
ning the assay. The sequencing is already cheaper, with prices
around $6 per sample, but prior overnight cultivation and DNA
extraction are still necessary additions. Therefore, sequencing is
still too demanding for routine clinical diagnostics.
Most importantly, this study demonstrates, possibly for the
first time, the direct identification of KPC variants from urine
samples without prior cultivation. Two different DNA extraction
kits (from Qiagen and Norgen) were tested for the extraction of
bacterial DNA from urine, followed directly by the microarray
analysis. Urine samples spiked with dilution series of different
reference strains were used as the testing material. In total, 132
extractions andmicroarray experiments were carried out to deter-
mine the limit of detection (LOD). In all experiments, the correct
KPC variant was identified from urine samples with as little as
1.6 104 CFU/ml. This LOD was obtained analyzing urine sam-
ples spiked with E. coli, whereas for K. pneumoniae, an even lower
limit of detection was observed (4  103 CFU/ml for the Qiagen
FIG 4 Limit of detection (LOD) from urine samples. Here, the results obtained from 132 microarray hybridizations carried out to determine the limit of
detection of thewhole assay are summarized. Two extraction kits (fromNorgen andQiagen)were used to isolateDNA fromurine samples spikedwith 3 different
strains carrying variants of the blaKPC gene. The fields marked with an “x” represent array experiments that did not fulfill all mathematical criteria for a correct
analysis and therefore were beyond the limit of detection (MM/PM 0.7, PM LOD). The numbers represents the KPC variants, which are identified here.
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kit and 360 CFU/ml for the Norgen kit). For the DNA extraction
of K. pneumoniae, the Norgen kit seemed to be slightly more sen-
sitive than the Qiagen kit. On average, only 80 CFU/ml urine was
needed when using the Norgen kit. If such a level of sensitivity is
not required, the Qiagen kit seems to be a lot more practicable for
routine extractions, with a much shorter handling time. Pheno-
typic tests have a lower detection limit (e.g., 4  101 to 9  102
CFU/ml for the CHROMagar KPC test), but the results can be
obtained only after 24 to 48 h or even later (26, 39). Bacterial loads
of more than 106 CFU/ml in urine are considered to be a clear
indication of a urinary tract infection (UTI) (38). Therefore, the
KPC microarray test presented in our study would be sensitive
enough to identify bacteria with KPC resistance from patients
with UTIs. Since only 1.7 ml urine was used for the analyses, the
limit of detection for both extraction methods could still be im-
proved further by increasing the amount of urine used for DNA
extraction. This would be especially interesting for the analysis of
symptomatic patients, where the presence of 100 CFU/ml is
enough to diagnose bacteriuria (38). The technology is, in princi-
ple, suitable for the direct testing of patient samples. However, the
performance ability, in terms of sensitivity and specificity, needs
to be further investigated in a separate study.
This study demonstrates the possibility of identifying single
KPC variants directly from urine samples, without prior cultiva-
tion, using a new DNA microarray. The total assay times of 5 h
(Qiagen extraction plus a DNA microarray) and 6 h (Norgen ex-
traction plus a DNA microarray) are a lot shorter than those of
classical methods of analyzing antimicrobial susceptibilities in
urine samples. The bacteria could be analyzed directly from urine
samples without further cultivation, and the exact KPC variant
could be identified, allowing for direct information toward possi-
ble treatment options and epidemiology. A larger study on urine
samples carrying KPC variants would further confirm the perfor-
mance of this test.
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